You are here

  • Home
  • Archive
  • Volume 81, Issue 11
  • Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor

Article Text

Article menu
Download PDFPDF
Correspondence
Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor
  1. Carlos Antonio Moura,
  2. Carlos Geraldo Moura
  1. Internal Medicine and Rheumatology, Hospital Santo Antonio, Salvador, Bahia, Brazil
  1. Correspondence to Dr Carlos Antonio Moura, Hospital Santo Antônio, Salvador, BA 40150360, Brazil; caggmoura{at}yahoo.com.br

https://doi.org/10.1136/annrheumdis-2020-217605

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    After reading the article from Braaten et al,1 we reinforce our idea that suspending checkpoint inhibitors (CPI) due to musculoskeletal symptoms, even if severe, may not always be a good alternative, since in addition to losing an option in the treatment of cancer we do not know if the symptoms will actually resolve with treatment interruption. Here we present a patient who developed severe polymyalgia rheumatic-like (PMR) symptoms 7 months after initiation of nivolumab for metastatic melanoma. Since it was a grade 3 immune-related adverse event according to the guidelines published in the Journal of Clinical Oncology,2 the oncologist initiated high-dose prednisone and opioids, considered interrupting …

    View Full Text

    Footnotes

    • Contributors Both authors contributed to the realisation of this article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Not commissioned; internally peer reviewed.